One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly

Background: Based on the CHIASMA OPTIMAL study, oral octreotide capsules (OOC) were recently approved in the US as a long-term maintenance therapy for patients with acromegaly previously responding to injectable octreotide or lanreotide, somatostatin receptor ligands (SRLs). Results on longer-term e...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Endocr Soc
Autores principales: Samson, Susan Leanne, Nachtigall, Lisa B, Fleseriu, Maria, Molitch, Mark E, Giustina, Andrea, Ludlam, William Henry, Patou, Gary, Haviv, Asi, Biermasz, Nienke, Kennedy, Laurence, Sever, Mojca Jensterle, Manning, Patrick John, Elenkova, Atanaska, Melmed, Shlomo, Strasburger, Christian Joseph
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2021
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090558/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1054
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares